SecBot SecBot

LCTX

Lineage Cell Therapeutics, Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. CA· CIK 0000876343 Biotech & Drug Discovery
$1.00 +0.01 (+1.01%)
Oct 23 4:00 PM ET · prev $0.9900
Market cap
$249.1M
Micro cap
Median target
🔒 Subscribers only
1 year
−41.2%
from $1.70 · Oct 24
30 days
+5.3%
from $0.9500
52-week range
$0.9000–1.96
−49% from high · low Oct 1
Avg volume 20D
1.50M
shares / day
Short interest
29.09M
≈11.5% of shares · −1.3%
Days to cover
15.8
at average volume
Insider net
+$24.4K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 3 reports · latest
Balance 0 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $24.4K at an average $1.63. No open-market sales. Price is 38% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 18 added (0 new), 11 trimmed or exited.

  • Short sellersSTEADY

    Short interest −1.3% to 29.09M shares. 15.8 days to cover, ≈11.5% of shares.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED13,186,895$17.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED5,299,457$6.9M
MILLENNIUM MANAGEMENT LLCTRIM3,018,567$4.0M
STATE STREET CORPDOUBLED2,314,180$3.0M
VANGUARD FIDUCIARY TRUST COADD1,668,629$2.2M
NORTHERN TRUST CORPDOUBLED1,656,651$2.2M
RENAISSANCE TECHNOLOGIES LLCTRIM1,344,829$1.8M
MARSHALL WACE, LLPTRIM1,282,347$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jul 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 4, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$24.4K
bought · 1 insider
$0
sold · 0 insiders
−38.5%
vs their $1.63 cost
DateInsiderTypeValue
Jul 1, 2026
Russell Angus C.
Director
AWARD125,000 sh
Jul 1, 2026
Bradsher Neal C
Director
AWARD125,000 sh
Jul 1, 2026
Jayasuriya Anula
Director
AWARD125,000 sh
Jul 1, 2026
Mulroy Michael H.
Director
AWARD125,000 sh
Jul 1, 2026
ANDREWS DEBORAH J
Director
AWARD125,000 sh
Jul 1, 2026
Amin Dipti
Director
AWARD125,000 sh
Mar 12, 2026
Culley Brian M
President and CEO
BUY$24.4K
Mar 5, 2026
Samuel George A. III
General Counsel and Secretary
AWARD900,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
29,093,018
shares short
-1.3%
vs prior settlement
15.8
days to cover
≈11.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 6, 2026 Earnings calendar
LCTX Q2 2026 Earnings Scheduled — 2026-08-06
Jul 1, 2026 Insider
Russell Angus C. was granted 125,000 shares
Director
Jul 1, 2026 Insider
Bradsher Neal C was granted 125,000 shares
Director
Jul 1, 2026 Insider
Jayasuriya Anula was granted 125,000 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
13,186,895 shares ($17.3M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
5,299,457 shares ($6.9M)
May 12, 2026 SEC
Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss of $4.8M ($0.02…
8-K — Impact 3/10
Mar 24, 2026 SEC
Lineage Cell Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to sell…
EFFECT — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 6, 2026
Earnings date
LCTX Q2 2026 Earnings Scheduled — 2026-08-06
May 12, 2026
Earnings date
LCTX Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
Earnings date
LCTX Q1 2026 Earnings Scheduled — 2026-05-07
Mar 5, 2026
Earnings date
LCTX Q4 2025 Earnings After Market Close — 2026-03-05

SecBot reports

3 filings · 0 bullish · 0 bearish · 1 mixed · 2 neutral
All LCTX filing & press-release reports (3)